Acute kidney injury (AKI) is a common complication in hospitalized patients, and has been consistently associated with an increased risk of death, *de novo* or worsening chronic kidney disease (CKD), and end-stage renal disease (ESRD).[@bib1], [@bib2], [@bib3], [@bib4], [@bib5] Patients discharged after an episode of AKI have a 40% increased risk of death in the 2 years following hospitalization,[@bib6] and a 50% to 60% increased risk of cardiovascular events, compared to patients who do not develop AKI.[@bib7] There are currently no effective therapies targeting established AKI; however, identifying and treating patients with CKD following an episode of AKI may improve health outcomes. Although recently published data suggested that nephrologist follow-up was associated with a 24% reduction in risk of death after hospitalization with severe AKI requiring dialysis,[@bib8] little is known about processes of care that modify outcomes after episodes of AKI.

Statins are effective for reducing cardiovascular morbidity and mortality in patients with CKD.[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18] We sought to evaluate whether the use of statins was associated with better outcomes among patients with CKD after AKI.

Methods {#sec1}
=======

Study Population and Data Sources {#sec1.1}
---------------------------------

We used the Alberta Kidney Disease Network population-based database, which has been described in detail elsewhere.[@bib19] The study cohort[@bib20] included all adults 18 years or older residing in Alberta who were admitted to the hospital between 1 July 2008 and 31 March 2011 and had an episode of AKI during hospitalization. To be eligible for inclusion, patients had to have at least 1 outpatient serum creatinine (Scr) measurement within 180 days prior to hospitalization to establish baseline kidney function, ≥ 1 measurement during the hospitalization to establish AKI, and ≥ 1 SCr, urine dipstick (udip), urine albumin to serum creatinine ratio (ACR), or urine protein to serum creatinine ratio (PCR) measurement in the follow-up period after hospital discharge to establish CKD. If participants had more than 1 hospitalization during this period, only the first was considered (index hospitalization). Participants who died or progressed to ESRD (estimated GFR \[eGFR\] \< 15 ml/min per 1.73 m^2^, chronic dialysis, prior kidney transplantation) before or during the index hospitalization were excluded. The cohort was restricted to patients who had CKD after an AKI episode. All subjects were followed up from the discharge date of their index hospitalization until 31 March 2013, with a minimum follow-up of 2 years.

The study was reviewed and approved by the institutional review boards at the Universities of Alberta and Calgary.

Assessment of Baseline Kidney Function {#sec1.2}
--------------------------------------

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used to determine the estimated glomerular filtration rate (eGFR).[@bib21] Baseline kidney function was defined as the mean outpatient Scr in the 180 days prior to the index hospitalization.

Identification of Acute Kidney Injury {#sec1.3}
-------------------------------------

AKI was identified by changes between baseline (pre-hospital) and peak in-hospital Scr. AKI was defined as an increase in serum creatinine by 50% or greater within 7 days or by 26.5 μmol/L within 48 hours and/or requirement for acute dialysis within 7 days of the index hospitalization. AKI severity was determined using the consensus criteria for AKI staging from the recently published Kidney Disease Improving Global Outcomes (KDIGO) AKI guidelines.[@bib22] Requirement for acute dialysis for AKI was determined using a validated approach, based on diagnosis and procedural administrative codes.[@bib23]

Assessment of CKD After AKI {#sec1.4}
---------------------------

The presence of CKD was assessed using Scr, urine ACR, urine PCR, or udip measured 90 days or more after the AKI episode to allow sufficient time for recovery of renal function ([Supplementary Figure S1](#appsec1){ref-type="sec"}). A 90-day time frame for recovery was chosen based on the Kidney Disease Outcomes Quality Initiative guidelines,[@bib24] which define CKD as a persistent decline in kidney function lasting \>90 days. If subjects had more than 1 outpatient SCr measurement, the measurement closest to 90 days was considered. Postdischarge CKD was defined as eGFR \< 60 ml/min/1.73 m^2^, ACR \> 30 mg/g, PCR \> 150 mg/g, or Udip \> trace, consistent with the KDIGO CKD guidelines.[@bib25]

Assessment of Medication Use After Discharge {#sec1.5}
--------------------------------------------

Prescription drug information was obtained from the Pharmaceutical Information Network (PIN) database. We classified statin exposure into the following groups: no previous prescription, new prescription (defined as at least 1 prescription within 2 years after discharge from the index hospitalization), stopping a previous prescription, and continuing a prescription. Patients were classified in the continuing prescription group if they had at least 1 prescription in the 6 months prior to admission and at least 1 prescription within 2 years postdischarge. High-dose statin was defined as the highest dosage for each statin drug ([Supplementary Table S1](#appsec1){ref-type="sec"}).

Assessment of Comorbid Conditions {#sec1.6}
---------------------------------

Relevant demographic characteristics, preexisting comorbid conditions (defined using validated algorithms),[@bib20], [@bib26] hospitalizations and outpatient physician visits (general practitioner as well as specialist visits), details of the index hospitalization including primary admission diagnosis, and intensive care unit stay were obtained using hospitalization data, claims files, and ambulatory care classification system files. We obtained primary International Classification of Diseases (10th revision) codes and used these to classify primary admission diagnoses using a previously published approach.[@bib26] Resource intensity weight, similar to diagnostic related group weight, was used to categorize acuity and severity of illness.[@bib27], [@bib28] Cholesterol level was defined as the mean outpatient total cholesterol in the 1 year prior to the index hospitalization. The cholesterol levels were classified into 5 risk categories according to the Framingham coronary heart disease risk score.[@bib29] Patients who did not have a cholesterol measurement during this time period were classified in an unknown group.

Outcomes {#sec1.7}
--------

The primary outcome was mortality; secondary outcomes included all-cause re-hospitalization and cardiovascular events. All outcomes were assessed after the discharge date of the index hospitalization. All-cause re-hospitalization was defined as any hospitalization occurring after the index hospitalization. All hospitalizations were identified using AH data. All-cause mortality was identified using administrative data sources. Cardiovascular events were defined as myocardial infarction, stroke, or revascularization procedure, as defined by validated algorithms.[@bib30], [@bib31], [@bib32]

Statistical Analysis {#sec1.8}
--------------------

Continuous variables were described using the mean and SD or the median with interquartile range as appropriate. Categorical variables were described as proportions of the cohort.

Multivariable Cox proportional hazard models with time-varying covariates were used to estimate the association between use of statin following index hospitalization and all-cause mortality, re-hospitalization, and cardiovascular events. The adjusted models included terms for age, sex, income quintile, aboriginal race, location of residency, health care use preceding the index hospitalization, Canadian Institute for Health Information resource intensity weight, intensive care unit admission during the index hospitalization, primary diagnostic code for hospitalization, procedures associated with AKI (cardiac catheterization, cardiac and abdominal aortic surgery), comorbid conditions, baseline kidney function (based on eGFR), cholesterol level, statin, angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), and β-blocker use in the 6 months preceding admission and following discharge ([Supplementary Figure S2](#appsec1){ref-type="sec"}). Time of origin was the discharge date for the index hospitalization. The proportional hazard assumption was evaluated and satisfied by examining plots of the log-negative-log within-group survivorship functions versus log-time.

First use of statin was used to update the exposure status during the course of the follow-up (i.e., a person on a statin would contribute person time to the "no statin use" before the first statin was prescribed and contribute person time to the "statin use" group after the first statin was prescribed). Patients were censored if they moved out of the province or reached the end of the study date (31 March 2013) for all outcomes. For the secondary outcomes, patients were censored if they died.

Analyses were repeated after further categorizing statin users into the following groups: new prescription postdischarge, continuing a previous prescription within 2 years postdischarge, and stopping use of a pre-hospital admission prescription. In the sensitivity analysis, we excluded patients who required acute dialysis to determine whether associations were similar in patients with less severe AKI. We also performed a sensitivity analysis excluding patients with proteinuria at any time during the study period to assess whether associations were similar in patients with non-proteinuric CKD. We repeated analyses after excluding patients who had any pre-existing cardiovascular disease, to examine findings in patients less likely to have pre-existing established cardiovascular disease. We compared the effect of statin use after stratifying the cohort according to whether patients had pre-existing CKD or *de novo* CKD (post-AKI) patients. We also compared outcomes in patients on high-dose versus low-dose statins.

Results {#sec2}
=======

Patient Characteristics {#sec2.1}
-----------------------

Between 1 July 2008 and 31 March 2011, there were 35,086 patients 18 years of age or older residing in Alberta with hospital-acquired AKI ([Figure 1](#fig1){ref-type="fig"}). Of these participants, 26,724 (76.2%) survived to 90 days after their AKI episode. The study cohort included 19,707 patients with CKD after the AKI episode: 12,148 (61.6%) had prior CKD and 7,559 (38.4%) had *de novo* CKD ([Figure 1](#fig1){ref-type="fig"}). The mean patient age was 69.9 years, 52.5% were men, and 83.7% lived in an urban location ([Table 1](#tbl1){ref-type="table"}). The mean number of hospitalizations during the 3 years preceding the index hospitalization was 1.7 (interquartile range \[IQR\] 0−2), and 18.4% of the cohort had a cardiovascular diagnostic code as the diagnosis most responsible for the index hospitalization. The majority of participants (80.9%) had hypertension, and a large number of patients had diabetes (42.6%), chronic heart failure (33.4%), and history of stroke or TIA (23.1%).Figure 1Selection of study population after episode of hospital-acquired acute kidney injury (AKI). CKD, chronic kidney disease; ESRD, end-stage renal disease.Table 1Characteristics of statin users and non−statin usersAll subjectsStatin usersNon−statin users*P* valueNumber of subjects (%)19,7077539 (38.3)12,168 (61.7)Age, yr, mean (SD)69.9 (14.9)70.7 (12)69.3 (16.5)\<0.01Sex, male (%)52.557.649.4\<0.01Aboriginal (%)3.83.24.2\<0.01Income quintile0.59 Lowest (level = 1) (%)24.924.625.1 Highest (level = 5) (%)15.915.616.0Urban location (%)83.784.383.20.04Healthcare access 3-year preceding hospital admission, mean (median, IQR) Number of hospitalizations1.7 (1, 0--2)1.7 (1, 0--2)1.8 (1, 0--2)0.02 Number of GP visits50.8 (36, 21--64)48.2 (37, 22--61)52.4 (36, 20--66)\<0.01 Number of nephrologist visits1.1 (0, 0--0)1.2 (0, 0--0)1 (0, 0--0)\<0.01 Number of cardiology visits3.1 (0, 0--2)4.6 (0, 0--5)2.2 (0, 0--1)\<0.01 Number of internist visits7.2 (3, 0--8)7.7 (3, 1--9)6.9 (2, 0--8)\<0.01 Number of emergency visits5.8 (3, 1--6)5.5 (3, 1--6)6 (3, 1--7)\<0.01 CIHI resource intensity weight, mean (SD)3.1 (6.3)2.7 (4.4)3.4 (7.2)\<0.01 Intensive care unit during hospitalization (%)18.924.815.3\<0.01Primary diagnostic code for hospitalization (%) Cardiovascular18.426.013.6\<0.01 Respiratory9.18.99.30.245 Gastrointestinal10.38.411.4\<0.01 Infectious disease4.63.85.1\<0.01 Cancer7.65.49.0\<0.01 Orthopedic4.64.94.40.09 Hematologic5.86.25.50.04 Genitourinary11.110.411.50.02 Injury/poisoning5.14.55.4\<0.01 Other disease23.521.424.7\<0.01Procedure or condition during index hospitalization (%) Sepsis4.83.85.4\<0.01 Cardiac surgery2.74.71.5\<0.01 Cardiac catheterization3.76.51.9\<0.01 Abdominal aortic aneurysm repair0.50.80.3\<0.01 Pneumonia10.710.011.20.01 Liver failure0.70.21.0\<0.01 Acute myocardial infraction10.116.36.3\<0.01 Noncardiac surgery17.015.318.1\<0.01Comorbid disease (%) Diabetes42.655.734.5\<0.01 Hypertension80.990.574.9\<0.01 Myocardial infarction13.019.88.8\<0.01 Chronic heart failure33.438.330.4\<0.01 Stroke or TIA23.125.921.4\<0.01 Cancer9.07.89.6\<0.01 Liver disease2.41.03.2\<0.01 Peripheral vascular disease7.210.05.4\<0.01Kidney function Baseline eGFR, ml/min/1.73 m^2^, mean (SD)62.3 (25.8)58.8 (23.1)64.4 (27.1)\<0.01 Prior CKD (%)61.666.258.8\<0.01 Prior CKD defined by eGFR33.334.032.9\<0.01 Prio CKD defined by proteinuria11.611.811.50.02 Prior CKD defined by eGFR and proteinuria16.720.314.5\<0.01 AKI stage (%)\<0.01 AKI stage 175.977.974.6\<0.01 AKI stage 214.813.515.6\<0.01 AKI stage 3 (no dialysis)7.16.27.6\<0.01 Dialysis2.32.42.20.37Baseline total cholesterol, mmol/l\<0.01 \<4.129.740.623.0\<0.01 4.15−5.1718.720.617.5\<0.01 5.18−6.2110.210.110.30.67 6.22−7.243.33.63.10.05 ≥7.251.31.91.0\<0.01 Unknown372345\<0.01[^1]

Primary Outcomes {#sec2.2}
----------------

More than one-half (54.4%) of the cohort were never prescribed a statin, 12.0% received a new prescription, and 26.3% were continued on a statin within 2 years after hospital discharge. Only 7.3% of previous statin prescriptions were not restarted after hospital discharge ([Table 2](#tbl2){ref-type="table"}).Table 2Number of patients (%) who were using statin before and after index hospitalizationWithin 6 months before admission2 yr After dischargeStatin6620 (33.6%)7539 (38.3%)Never prescribedNew prescriptionStopping previous prescriptionContinuing prescriptionStatin10,729 (54.4%)2358 (12.0%)1439 (7.3%)5181 (26.3%)

Over a total of 53,700 person-years of follow up, the adjusted hazard ratio for mortality associated with statin use after hospital discharge, compared with no statin use, was 0.74 (95% confidence interval \[CI\], 0.69, 0.79). Statin use after hospitalization was also associated with a lower risk of all cause re-hospitalization (hazard ratio \[HR\], 0.90; 95% CI, 0.85, 0.94) ([Table 3](#tbl3){ref-type="table"}).Table 3Hazard ratios of statin use after hospital dischargeOutcomeAdjusted hazard ratio (95% CI)Number of eventsFollow-up time in person-yrCrude hazard ratio (95% CI)Survival0.74 (0.69--0.79)675853700.940.75 (0.71--0.79)All cause re-hospitalization0.90 (0.85--0.94)15,25625144.770.94 (0.9--0.97)Cardiovascular event0.95 (0.87--1.04)349348764.461.54 (1.43--1.65)[^2][^3][^4]

Both a new statin prescription (HR, 0.73; 95% CI, 0.66, 0.80) and continuing a previous prescription (HR, 0.76; 95% CI, 0.71, 0.81) after hospital discharge was associated with better survival compared to no statin use. There was also lower all-cause re-hospitalization in both patients who were given a new statin prescription or continued on a previous statin prescription after hospital discharge, compared to no statin use ([Table 4](#tbl4){ref-type="table"}).Table 4Hazard ratios of statin use for never prescribed, new prescription, stopping previous prescription, or continuing previous prescriptionOutcomeStatin useHazard ratio (95% CI)SurvivalNever prescribed1New prescription0.73 (0.66--0.80)Stopping previous prescription1.00 (0.91--1.09)Continuing prescription0.76 (0.71--0.81)All cause re-hospitalizationNever prescribed1New prescription0.85 (0.79--0.91)Stopping previous prescription0.98 (0.93--1.03)Continuing prescription0.91 (0.87--0.95)Cardiovascular eventNever prescribed1New prescription0.92 (0.81--1.05)Stopping previous prescription1.01 (0.90--1.13)Continuing prescription1.00 (0.92--1.10)Prescription6 mo Before admission2 yr After dischargeNever prescribedNo prescriptionNo prescriptionNew prescriptionNo prescriptionAt least 1 prescriptionStopping previous prescriptionAt least 1 prescriptionNo prescriptionContinuing prescriptionAt least 1 prescriptionAt least 1 prescription[^5][^6][^7]

Sensitivity Analysis {#sec2.3}
--------------------

In the sensitivity analysis excluding patients with cardiovascular disease (n = 15,116), those who used a statin after hospital discharge had lower mortality (HR, 0.70; 95% CI, 0.64, 0.76), and all-cause re-hospitalization (HR, 0.90; 95% CI, 0.85, 0.95) ([Table 5](#tbl5){ref-type="table"}). Exclusion of patients with the most severe AKI requiring dialysis (n = 19,250) and proteinuria before or after the index hospitalization (n = 15,792) did not change results for survival, re-hospitalization rates, or cardiovascular events ([Table 5](#tbl5){ref-type="table"}).Table 5Hazard ratios of statin use for patients not requiring dialysis, with no proteinuria and no pre-existing cardiovascular diseaseHazard ratio (95% CI)Excluding dialysis patientsExcluding patients with proteinuriaPatients without pre-existing CVD[a](#tbl5fna){ref-type="table-fn"}Number of subjects19,25015,79215,116Survival0.74 (0.69--0.79)0.74 (0.69--0.80)0.70 (0.64--0.76)All-cause rehospitalization0.89 (0.85--0.94)0.89 (0.84--0.93)0.90 (0.85--0.95)Cardiovascular events0.96 (0.87--1.05)0.95 (0.86--1.04)0.92 (0.81--1.05)[^8][^9]

Statin use was associated with lower mortality and all cause re-hospitalization in both patients with pre-existing CKD and *de novo* CKD. Statin use was not associated with lower risk of cardiovascular events in patients with pre-existing or *de novo* CKD ([Table 6](#tbl6){ref-type="table"}).Table 6Hazard ratios of statin use after hospital discharge for patients with prior chronic kidney disease (CKD) and *de novo* CKDOutcomeHazard ratio (95% CI)Prior CKD*De novo* CKDNumber of subjects12,1487559Survival0.76 (0.70--0.83)0.67 (0.59--0.77)All cause rehospitalization0.90 (0.85--0.96)0.86 (0.79--0.94)Cardiovascular events0.96 (0.87--1.07)0.92 (0.77--1.10)

Low-dose and high-dose statin had similar effects on mortality, all-cause re-hospitalization, and cardiovascular events ([Table 7](#tbl7){ref-type="table"}).Table 7Hazard ratios of high- and low-dose statin useOutcomeHazard ratio (95% CI)Number of subjectsSurvival Low-dose0.74 (0.69--0.79)6651 High-dose0.71 (0.62--0.82)888 No statin1.00 \[reference\]12,168 High-dose versus low-dose0.97 (0.84--1.11)--All-cause rehospitalization Low-dose0.89 (0.85--0.94)4993 High-dose0.91 (0.82--1.00)679 No statin1.00 \[reference\]14,035 High-dose versus low-dose1.01 (0.92--1.12)--Cardiovascular events Low-dose0.94 (0.85--1.03)6310 High-dose1.10 (0.94--1.29)815 No statin1.00 \[reference\]12,582 High-dose versus low-dose1.18 (1.02--1.37)--[^10][^11]

Discussion {#sec3}
==========

Using a large population-based cohort we characterized statin use in patients with CKD after an episode of AKI in the hospital. Over a follow-up period of at least 2 years after discharge, AKI survivors who were dispensed a statin after the index hospitalization had a lower risk of death compared to those with no statin use. Statin use was also associated with a decreased risk of all-cause re-hospitalization.

The risks of developing CKD following an episode of AKI are well documented in both pediatric[@bib33] and adult[@bib34] cohort studies. Recent work from our group confirms that failure to recover renal function to within 25% of baseline SCr within 90 days after moderate to severe AKI is associated with an increased risk of long-term mortality (adjusted HR, 1.26; 95% CI, 1.10, 1.43).[@bib35] Management of CKD after AKI may mitigate the risks of progressive CKD and increased mortality. A recently published systematic review of randomized controlled trials confirmed the importance of ACEi, ARB, β-blocker, and statin use as effective therapies for the treatment of CKD stages 1 to 3.[@bib36] Statins showed reduced mortality and cardiovascular events versus placebo or control in patients with impaired eGFR. To date no studies have examined the effect of statin use in AKI survivors.

Conservative population based estimates of AKI incidence in hospitalized adults are in the range of 3,000 per 100,000 person years,[@bib37] and the majority of these patients will survive hospital discharge. Recent KDIGO guidelines recommended that patients be followed up 3 months after an AKI episode to assess for CKD; however, there has been a lack of information to guide the care that these patients should receive. Based on our results, AKI survivors may benefit from statin therapy postdischarge, an intervention that does not require specialized care and could be readily implemented. In our study, only 39.1% of the cohort who had CKD after AKI were dispensed a statin within 2 years of their index hospitalization, despite their high risk profile for cardiovascular disease, and despite recently released international guidelines for lipid management in CKD, which recommends that adults \>50 years of age with eGFR \< 60 ml/min/1.73 m^2^ should be treated with a statin.[@bib38] Furthermore, 5.8% of statin prescriptions were not restarted postdischarge. We also observed better survival in the subgroup of patients who were given a new statin prescription compared to those who did not receive a statin. These findings suggest that there is an opportunity to improve postdischarge care in AKI survivors with CKD.

Several recent studies have suggested that AKI is a risk factor for cardiovascular disease and future cardiovascular events.[@bib39] Our results showed a trend toward a reduction in cardiovascular events in patients who received a statin, although it was not significant. This may be explained by the fact that patients who develop AKI and progress to CKD likely have undetected or early cardiovascular disease.

Despite reporting outcomes adjusted for many important confounders, there are some limitations to our analysis, related primarily to the retrospective use of administrative and laboratory data and observational design. First, entry into the cohort was limited to subjects who had ≥1 outpatient SCr measurement within 180 days prior to hospitalization and \>1 inpatient SCr measurement performed as part of hospital care in Alberta. However, repeated measurements of SCr are common in patients hospitalized for acute medical and surgical problems, and based on prior work, patients who do not have SCr drawn after hospitalization have outcomes similar to those who do not have AKI; therefore, it is likely that we were able to capture all AKI patients at high risk for poor outcomes after discharge. Second, we were unable to obtain measures of some potentially important covariates such as blood pressure, urine output, nutritional status, and deconditioning after hospitalization with AKI. Third, as patients were not randomized to different processes of care, there is potential for treatment-by-indication bias, whereby certain patient characteristics prompt differences in prescription of a statin, thereby introducing confounding. However, because we expect that patients at higher cardiovascular risk are more likely to receive a statin, we expect that the direction of bias in our study is toward the null, and thus the strength of any observed associations between medications and outcomes is likely conservative. It is also possible that statin use was a marker of better follow-up care. Finally, our exposure was defined as a dispensed prescription, and the rate of compliance among patients in the statin group is likely not 100%.

Conclusions {#sec4}
===========

The use of a statin in AKI survivors who progress to CKD after hospital discharge is associated with lower mortality and re-hospitalization. This observation requires further evaluation in prospective studies evaluating postdischarge care strategies for AKI survivors. In particular, our results suggest a need for a trial to evaluate treatment with statin in survivors of AKI, to determine whether this intervention improves long-term outcomes in high-risk patients.
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**Figure S1.** Distribution of the first abnormal laboratory test results (SCr/udip/umcr/pcr) after AKI episode.

**Figure S2.** Cumulative proportion of subjects who used angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, statin, and β-blocker postdischarge.
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[^1]: AKI, acute kidney injury; CIHI, Canadian Institute for Health Information; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; TIA, transient ischemic attack.

[^2]: CI, confidence interval.

[^3]: Adjusted factors: Angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), β-blocker, and statin use within 6 months before admission, ACEI/ARB and β-blocker after discharge, age, sex, income quintile, urban location, health care use 3 years before hospital admission, Canadian Institute for Health Information resource intensity weight, intensive care unit, primary diagnostic code for hospitalization, procedure or condition during index hospitalization, comorbid disease, baseline kidney function (estimated glomerular filtration rate), and total cholesterol risk categories.

[^4]: Separate Cox proportional hazard models with medication use as time-varying covariates were fit for the outcome of all-cause mortality, all-cause re-hospitalization, and cardiovascular events. All patients were followed up for at least 2 years starting at the date of hospital discharge, with further censoring for death, outmigration from Alberta, and the end of study (31 March 2013) in the model fit of all-cause re-hospitalization and cardiovascular events, and for outmigration from Alberta and end of study in the model fit for mortality.

[^5]: CI, confidence interval.

[^6]: Adjusted factors: Angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB), β-blocker and statin use within 6 months before admission, ACEI/ARB and β-blocker after discharge, age, sex, income quintile, urban location, health care use 3 years before hospital admission, Canadian Institute for Health Information resource intensity weight, intensive care unit, primary diagnostic code for hospitalization, procedure or condition during index hospitalization, comorbid disease, baseline kidney function (estimated glomerular filtration rate), and total cholesterol risk categories.

[^7]: Separate Cox proportional hazard models with medication use as time-varying covariates were fit for the outcomes of all-cause mortality, all-cause re-hospitalization, and cardiovascular events. All patients were followed up for at least 2 years starting at the date of hospital discharge, with further censoring for death, outmigration from Alberta, and the end of study (31 March 2013) in the model fit of all-cause re-hospitalization and cardiovascular events, and for outmigration from Alberta and end of study in the model fit for mortality.

[^8]: CI, confidence interval; CVD, cardiovascular disease.

[^9]: Pre-existing CVD includes acute myocardial infarction, coronary artery bypass grafting, cardiac catherization, congestive heart failure, cerebrovascular accident (including all stroke-related events), and percutaneous coronary interventions in the 3 years before admission and during the index hospitalization.

[^10]: CI, confidence interval.

[^11]: A total of 888 patients used high-dose statin before death occurred or the end of the follow-up period; 679 patients used high-dose statin before re-hospitalization after discharge from the index hospitalization or the end of the follow-up period; and 815 patients used high-dose statin before a cardiovascular event occurred or the end of the follow-up period.
